S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
Free Trial

Phathom Pharmaceuticals (PHAT) Earnings Date, Estimates & Call Transcripts

→ Here’s how to start a “Weekend Side Hustle” from your sofa (From DTI) (Ad)
Free PHAT Stock Alerts
$9.17
-0.31 (-3.27%)
(As of 10:40 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
May. 8Estimated
Actual EPS
(Mar. 7)
-$0.80 Beat By $0.12
Consensus EPS
(Mar. 7)
-$0.92
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

PHAT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PHAT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Phathom Pharmaceuticals Analyst EPS Estimates

Current Year EPS Consensus Estimate:($4.22) EPS
Next Year EPS Consensus Estimate: ($3.24) EPS

PHAT Earnings Date and Information

Phathom Pharmaceuticals last posted its quarterly earnings results on March 7th, 2024. The reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.12. The business had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.93 million. Phathom Pharmaceuticals has generated ($3.88) earnings per share over the last year (($3.88) diluted earnings per share). Earnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($4.22) to ($3.24) per share. Phathom Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off prior year's report dates.

Phathom Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/8/2024
Estimated)		------- 
3/7/2024Q4 2023($0.92)($0.80)+$0.12($0.21)$0.93 million$0.68 million    
11/9/2023Q3 2023($0.95)($0.76)+$0.19($0.76)--
8/10/2023Q2 2023($0.95)($0.84)+$0.11($0.84)--
5/10/2023Q1 2023($1.34)($0.89)+$0.45($0.89)--
2/28/2023Q4 2022($1.50)($1.33)+$0.17($1.33)--
11/8/2022Q3 2022-($1.32)($1.32)($1.32)--
8/2/2022Q2 2022-($1.33)($1.33)($1.33)--
5/10/2022Q1 2022-($1.07)($1.07)($1.07)--
3/1/2022Q4 2021($0.86)($0.95)($0.09)($0.95)--
11/8/2021Q3 2021($1.05)($0.98)+$0.07($0.98)--
8/10/2021Q2 2021($1.07)($1.00)+$0.07($1.00)--
5/11/2021Q1 2021($1.11)($0.96)+$0.15($0.96)--

Phathom Pharmaceuticals Earnings - Frequently Asked Questions

When is Phathom Pharmaceuticals's earnings date?

Phathom Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off last year's report dates. Learn more on PHAT's earnings history.

Did Phathom Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Phathom Pharmaceuticals (NASDAQ:PHAT) reported ($0.80) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.92) by $0.12. Learn more on analysts' earnings estimate vs. PHAT's actual earnings.

How can I listen to Phathom Pharmaceuticals's earnings conference call?

The conference call for Phathom Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Phathom Pharmaceuticals's conference call transcript?

The conference call transcript for Phathom Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Phathom Pharmaceuticals generate each year?

Phathom Pharmaceuticals (NASDAQ:PHAT) has a recorded annual revenue of $680,000.00.

How much profit does Phathom Pharmaceuticals generate each year?

Phathom Pharmaceuticals (NASDAQ:PHAT) has a recorded net income of -$201.59 million. PHAT has generated -$3.88 earnings per share over the last four quarters.

What is Phathom Pharmaceuticals's EPS forecast for next year?

Phathom Pharmaceuticals's earnings are expected to grow from ($4.22) per share to ($3.24) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:PHAT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research